Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0195 in Participants With or Without Elevated Lipoprotein(a)
NCT07804160Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Aug 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, double-blind trial of SAL0195 in elevated lipoprotein(a) (Lp(a)) (10 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Number of Participants With Clinically Significant Changes in Vital Signs, Incidence and Severity of Treatment-Emergent Adverse Events and 4 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
SAL0195
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT07804160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804160.